Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Trial

Annovis Bio Inc. (NYSE: ANVS) has achieved significant milestones in its pivotal Phase 3 clinical trial for early Alzheimer's disease, with all 84 U.S. clinical sites now fully activated and actively enrolling patients. The company reported that most sites are already treating participants, and the first group of patients has successfully completed the 6-month treatment phase of the study. This progress maintains the company's timeline to deliver symptomatic efficacy data in the second half of 2026, representing a crucial step forward in developing treatments for Alzheimer's disease, which affects millions of patients worldwide and currently lacks effective therapeutic options.

The trial's advancement to 25% completion demonstrates strong execution across the clinical network and continued momentum toward bringing the investigational drug buntanetap to patients suffering from neurodegenerative conditions. CEO Maria Maccecchini emphasized the importance of this progress in the company's mission to address the urgent need for effective Alzheimer's therapies. The full activation of all clinical sites ensures that patient enrollment can proceed at maximum capacity, potentially accelerating the timeline for regulatory review and eventual patient access if the trial proves successful.

Buntanetap represents a novel approach to treating neurodegenerative diseases by targeting multiple pathological proteins simultaneously, potentially offering broader therapeutic benefits compared to single-target approaches. The successful completion of the first patient cohort's treatment phase provides early validation of the trial's feasibility and patient retention capabilities, both critical factors in Alzheimer's clinical research where high dropout rates have historically challenged study outcomes. For more detailed information about the company's research programs, visit https://www.annovisbio.com.

The Alzheimer's disease therapeutic landscape remains challenging, with few treatment options available and many late-stage clinical failures in recent years. Annovis Bio's progress comes at a time when the medical community continues to seek effective interventions that can meaningfully improve symptoms and slow disease progression. The company's ability to maintain its projected timeline for data readout in 2026 positions it competitively in the neurodegenerative disease space, where timely development and regulatory approval are crucial for addressing the growing global burden of Alzheimer's disease. Investors and patients can follow additional company developments through the newsroom at https://ibn.fm/ANVS.